CoChat
Sign Up
Cited by 41Barrier Structure and Function StudiesNanoparticle-Based Drug DeliveryRNA Interference and Gene Delivery

Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models

Open access
Israel, Liron L., Galstyan, Anna, Cox, Alysia, Shatalova, Ekaterina S., Sun, Tao, Rashid, Mohammad-Harun, Grodzinski, Zachary, Chiechi, Antonella +6 more·2022·ACS Nano
DOI 10.1021/acsnano.1c10034PMC PMC9413444
Open this paper in CoChat — free accountOpen PDF

Abstract

brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer's disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsnano.1c10034

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Six peptide vectors attached to poly(β-l-malic acid)-trileucine polymer target LRP-1, transferrin receptor, bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex.

    “These peptides could act the specific targeting function, aiming at low-density lipoprotein receptor-related protein-1, transferrin receptor, bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex.”

    From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [184]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 93

  1. Siegal T.; Zylber-Katz E. Strategies for Increasing Drug Delivery to the Brain. Clinical pharmacokinetics 2002, 41 (3), 171– 186. 10.2165/00003088-200241030-00002. 11929318 · DOI
  2. Siegal T.; Horowitz A.; Gabizon A. Doxorubicin Encapsulated in Sterically Stabilized Liposomes for the Treatment of a Brain Tumor Model: Biodistribution and Therapeutic Efficacy. Journal of neurosurgery 1995, 83 (6), 1029– 1037. 10.3171/jns.1995.83.6.1029. 7490617 · DOI · Paper page
  3. Webster D. M.; Sundaram P.; Byrne M. E. Injectable nNanomaterials for Drug Delivery: Carriers, Targeting Moieties, and Therapeutics. Eur. J. Pharm. Biopharm. 2013, 84 (1), 1– 20. 10.1016/j.ejpb.2012.12.009. 23313176 · DOI
  4. Wong H. L.; Wu X. Y.; Bendayan R. Nanotechnological Advances for the Delivery of CNS Therapeutics. Adv. Drug Delivery Rev. 2012, 64 (7), 686– 700. 10.1016/j.addr.2011.10.007. 22100125 · DOI · Paper page
  5. Walkey C. D.; Chan W. C. W. Understanding and Controlling the Interaction of Nanomaterials with Proteins in a Physiological Environment. Chem. Soc. Rev. 2012, 41, 2780 10.1039/C1CS15233E. 22086677 · DOI · Paper page
  6. Yu Y. J.; Zhang Y.; Kenrick M.; Hoyte K.; Luk W.; Lu Y.; Atwal J.; Elliott J. M.; Prabhu S.; Watts R. J. Boosting Brain Uptake of a Therapeutic Antibody by Reducing its Affinity for a Transcytosis Target. Science translational medicine 2011, 3 (84), 84ra44– 84ra44. 10.1126/scitranslmed.3002230. 21613623 · DOI · Paper page
  7. Zenaro E.; Piacentino G.; Constantin G. The Blood-Brain Barrier in Alzheimer’s Disease. Neurobiology of Disease 2017, 107, 41– 56. 10.1016/j.nbd.2016.07.007. 27425887 PMC5600438 · DOI · Paper page
  8. Zipser B.; Johanson C.; Gonzalez L.; Berzin T.; Tavares R.; Hulette C.; Vitek M.; Hovanesian V.; Stopa E. Microvascular Injury and Blood–Brain Barrier Leakage in Alzheimer’s Disease. Neurobiology of aging 2007, 28 (7), 977– 986. 10.1016/j.neurobiolaging.2006.05.016. 16782234 · DOI · Paper page
  9. Zuroff L.; Daley D.; Black K. L.; Koronyo-Hamaoui M. Clearance of Cerebral Aβ in Alzheimer’s Disease: Reassessing the Role of Microglia and Monocytes. Cell. Mol. Life Sci. 2017, 74 (12), 2167– 2201. 10.1007/s00018-017-2463-7. 28197669 PMC5425508 · DOI
  10. Carare R. O.; Koronyo-Hamaoui M.; Hainsworth A.; Holtzman D.; Ihara M.; Jefferson A.; Kalaria R. N.; Kipps C.; Kanninen K.; Leinonen V.; McLaurin J.; Miners S.; Malm T.; Nicoll J. A. R.; Piazza F.; Paul-Visse G.; Saito S.; Shih A.; Scholtzova H.; Snyder H.; Snyder P.; Zlokovic B.; et al. Cerebrovascular Disease and the Failure of Elimination of Amyloid-β From the Brain and Retina with Age and Alzheimer’s Disease. Opportunities for Therapy. Alzheimer’s Dement (Amst). 2020, 12, e12053. 32775596 PMC7396859
  11. Shi H.; Koronyo Y.; Fuchs D. T.; Sheyn J.; Wawrowsky K.; Lahiri S.; Black K. L.; Koronyo-Hamaoui M. Retinal Capillary Degeneration and Blood-Retinal Barrier Disruption in Murine Models of Alzheimer’s Disease. Acta Neuropathol Commun. 2020, 8, 202 10.1186/s40478-020-01076-4. 33228786 PMC7686701 · DOI
  12. Maeda H.; Bharate G. Y.; Daruwalla J. Polymeric Drugs for Efficient Tumor-Targeted Drug Delivery Based on EPR-Effect. Eur. J. Pharm. Biopharm. 2009, 71 (3), 409– 419. 10.1016/j.ejpb.2008.11.010. 19070661 · DOI
  13. Huynh E.; Zheng G. Cancer Nanomedicine: Addressing the Dark Side of the Enhanced Permeability and Retention Effect. Nanomedicine 2015, 10 (13), 1993– 1995. 10.2217/nnm.15.86. 26096565 · DOI · Paper page
  14. DeSantis C. E.; Lin C. C.; Mariotto A. B.; Siegel R. L.; Stein K. D.; Kramer J. L.; Alteri R.; Robbins A. S.; Jemal A. Cancer Treatment and Survivorship Statistics, 2014. CA: A cancer journal for clinicians 2014, 64 (4), 252– 271. 24890451
  15. Nichols J. W.; Bae Y. H. EPR: Evidence and Fallacy. J. Controlled Release 2014, 190, 451– 464. 10.1016/j.jconrel.2014.03.057. 24794900 · DOI · Paper page
  16. Danhier F. To Exploit the Tumor Microenvironment: Since the EPR Effect Fails in the Clinic, What is the Future of Nanomedicine?. J. Controlled Release 2016, 244, 108– 121. 10.1016/j.jconrel.2016.11.015. 27871992 · DOI · Paper page
  17. Ramanathan A.; Nelson A. R.; Sagare A. P.; Zlokovic B. V. Impaired Vascular-Mediated Clearance of Brain Amyloid Beta in Alzheimer’s Disease: the Role, Regulation and Restoration of LRP1. Frontiers in Aging Neuroscience 2015, 7, 136 10.3389/fnagi.2015.00136. 26236233 PMC4502358 · DOI · Paper page
  18. Grimmer T.; Goldhardt O.; Guo L.-H.; Yousefi B. H.; Förster S.; Drzezga A.; Sorg C.; Alexopoulos P.; Förstl H.; Kurz A. LRP-1 Polymorphism is Associated with Global and Regional Amyloid Load in Alzheimer’s Disease in Humans in-Vivo. NeuroImage: Clinical 2014, 4, 411– 416. 10.1016/j.nicl.2014.01.016. 24596678 PMC3939495 · DOI
  19. Daniels T. R.; Delgado T.; Rodriguez J. A.; Helguera G.; Penichet M. L. The Transferrin Receptor Part I: Biology and Targeting with Cytotoxic Antibodies for the Treatment of Cancer. Clinical Immunology 2006, 121 (2), 144– 158. 10.1016/j.clim.2006.06.010. 16904380 · DOI
  20. Inoue S.; Patil R.; Portilla-Arias J.; Ding H.; Konda B.; Espinoza A.; Mongayt D.; Markman J. L.; Elramsisy A.; Phillips H. W.; Black K. L.; Holler E.; Ljubimova J. Y. Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer. PLoS One 2012, 7 (2), e31070 10.1371/journal.pone.0031070. 22355336 PMC3280290 · DOI
  21. Fabrichny I. P.; Leone P.; Sulzenbacher G.; Comoletti D.; Miller M. T.; Taylor P.; Bourne Y.; Marchot P. Structural Analysis of the Synaptic Protein Neuroligin and its β-Neurexin Complex: Determinants for Folding and Cell Adhesion. Neuron 2007, 56 (6), 979– 991. 10.1016/j.neuron.2007.11.013. 18093521 PMC2703725 · DOI
  22. Deane R.; Du Yan S.; Submamaryan R. K.; LaRue B.; Jovanovic S.; Hogg E.; Welch D.; Manness L.; Lin C.; Yu J.; Zhu H.; Ghiso J.; Frangione B.; Stern A.; Schmidt A. M.; Armstrong D. L.; Arnold B.; Liliensiek B.; Nawroth P.; Hofman F.; et al. RAGE Mediates Amyloid-β Peptide Transport Across the Blood-Brain Barrier and Accumulation in Brain. Nature Medicine 2003, 9 (7), 907– 913. 10.1038/nm890. 12808450 · DOI · Paper page
  23. Wan W.; Cao L.; Liu L.; Zhang C.; Kalionis B.; Tai X.; Li Y.; Xia S. Aβ1–42 Oligomer-Induced Leakage in an in Vitro Blood–Brain Barrier Model is Associated with Up-Regulation of RAGE and Metalloproteinases, and Down-Regulation of Tight Junction Scaffold Proteins. Journal of neurochemistry 2015, 134 (2), 382– 393. 10.1111/jnc.13122. 25866188 · DOI
  24. Boado R. J.; Li J. Y.; Nagaya M.; Zhang C.; Pardridge W. M. Selective Expression of the Large Neutral Amino Acid Transporter at the Blood–Brain Barrier. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (21), 12079 10.1073/pnas.96.21.12079. 10518579 PMC18415 · DOI
  25. Johnsen K. B.; Burkhart A.; Melander F.; Kempen P. J.; Vejlebo J. B.; Siupka P.; Nielsen M. S.; Andresen T. L.; Moos T. Targeting Transferrin Receptors at the Blood-Brain Barrier Improves the Uptake of Immunoliposomes and Subsequent Cargo Transport into the Brain Parenchyma. Sci. Rep 2017, 7 (1), 10396 10.1038/s41598-017-11220-1. 28871203 PMC5583399 · DOI
  26. Zhang F.; Xu C.-L.; Liu C.-M. Drug Delivery Strategies to Enhance the Permeability of the Blood–Brain Barrier for Treatment of Glioma. Drug Design, Development and Therapy 2015, 9, 2089– 2100. 10.2147/DDDT.S79592. 25926719 PMC4403597 · DOI
  27. Ulbrich K.; Hekmatara T.; Herbert E.; Kreuter J. Transferrin-and Transferrin-Receptor-Antibody-Modified Nanoparticles Enable Drug Delivery Across the Blood–Brain Barrier (BBB). Eur. J. Pharm. Biopharm. 2009, 71 (2), 251– 256. 10.1016/j.ejpb.2008.08.021. 18805484 · DOI · Paper page
  28. Tian X.; Nyberg S.; Sharp P. S.; Madsen J.; Daneshpour N.; Armes S. P.; Berwick J.; Azzouz M.; Shaw P.; Abbott N. J.; Battaglia G. LRP-1-Mediated Intracellular Antibody Delivery to the Central Nervous System. Sci. Rep 2015, 5, 11990 10.1038/srep11990. 26189707 PMC4507173 · DOI
  29. Ong Z. Y.; Chen S.; Nabavi E.; Regoutz A.; Payne D. J.; Elson D. S.; Dexter D. T.; Dunlop I. E.; Porter A. E. Multibranched Gold Nanoparticles with Intrinsic LAT-1 Targeting Capabilities for Selective Photothermal Therapy of Breast Cancer. ACS Appl. Mater. Interfaces 2017, 9 (45), 39259– 39270. 10.1021/acsami.7b14851. 29058874 · DOI
  30. Geier E. G.; Schlessinger A.; Fan H.; Gable J. E.; Irwin J. J.; Sali A.; Giacomini K. M. Structure-Based Ligand Discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (14), 5480– 5485. 10.1073/pnas.1218165110. 23509259 PMC3619328 · DOI
  31. Marco S.; Skaper S. D. Amyloid β-Peptide1–42 Alters Tight Junction Protein Distribution and Expression in Brain Microvessel Endothelial Cells. Neuroscience letters 2006, 401 (3), 219– 224. 10.1016/j.neulet.2006.03.047. 16644119 · DOI
  32. Yamazaki Y.; Shinohara M.; Shinohara M.; Yamazaki A.; Murray M. E.; Liesinger A. M.; Heckman M. G.; Lesser E. R.; Parisi J. E.; Petersen R. C. Selective Loss of Cortical Endothelial Tight Junction Proteins During Alzheimer’s Disease Progression. Brain 2019, 142 (4), 1077– 1092. 10.1093/brain/awz011. 30770921 PMC6439325 · DOI · Paper page
  33. Israel L. L.; Braubach O.; Galstyan A.; Chiechi A.; Shatalova E. S.; Grodzinski Z.; Ding H.; Black K. L.; Ljubimova J. Y.; Holler E. A Combination of Tri-Leucine and Angiopep-2 Drives a Poly-Anionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier. ACS Nano 2019, 13 (2), 1253– 1271. 10.1021/acsnano.8b06437. 30633492 PMC7641102 · DOI
  34. Galstyan A.; Markman J. L.; Shatalova E. S.; Chiechi A.; Korman A. J.; Patil R.; Klymyshyn D.; Tourtellotte W. G.; Israel L. L.; Braubach O.; Ljubimov V. A.; Mashouf L. A.; Ramesh A.; Grodzinski Z. B.; Penichet M. L.; Black K. L.; Holler E.; Sun T.; Ding H.; Ljubimov A. V.; et al. Blood–Brain Barrier Permeable Nano Immunoconjugates Induce Local Immune Responses for Glioma Therapy. Nat. Commun. 2019, 10 (1), 3850 10.1038/s41467-019-11719-3. 31462642 PMC6713723 · DOI
  35. Ding H.; Portilla-Aries J.; Patil R.; Black K. L.; Ljubimova J. Y.; Holler E. Polymalic Acid Peptide Copolymers: Design and Optimization for Endosomolytic Drug Delivery. Biomaterials 2011, 32, 5269– 5278. 10.1016/j.biomaterials.2011.03.073. 21514661 PMC4110056 · DOI
  36. Ding H.; Portilla-Arias J.; Patil R.; Black K. L.; Ljubimova J. Y.; Holler E. Distinct Mechanisms of Membrane Permeation Induced by Two Polymalic Acid Copolymers. Biomaterials 2013, 34, 217– 225. 10.1016/j.biomaterials.2012.08.016. 23063368 PMC3487713 · DOI
  37. Ljubimova J. Y.; Portilla-Arias J.; Patil R.; Ding H.; Inoue S.; Markman J. L.; Rekechenetskiy A.; Konda B.; Gangalum P. R.; Chesnokova A.; Ljubimov A. V.; Black K. L.; Holler E. Toxicity and Efficacy Evaluation of Multiple Targeted Polymalic Acid Conjugates for Triple-Negative Breast Cancer Treatment. J. Drug Targeting 2013, 21 (10), 956– 967. 10.3109/1061186X.2013.837470. PMC4043297 24032759 · DOI
  38. Demeule M.; Regina A.; Che C.; Poirier J.; Nguyen T.; Gabathuler R.; Castaigne J.-P.; Beliveau R. Identification and Design of Peptides as a New Drug Delivery System for the Brain. Journal of Pharmacology and Experimental Therapeutics 2008, 324 (3), 1064– 1072. 10.1124/jpet.107.131318. 18156463 · DOI
  39. Demeule M.; Currie J. C.; Bertrand Y.; Che C.; Nguyen T.; Regina A.; Gabathuler R.; Castaigne J. P.; Beliveau R. Involvement of the Low-Density Lipoprotein Receptor-Related Protein in the Transcytosis of the Brain Delivery Vector Angiopep-2. Journal of neurochemistry 2008, 106 (4), 1534– 1544. 10.1111/j.1471-4159.2008.05492.x. 18489712 · DOI · Paper page
  40. Demeule M.; Beaudet N.; Régina A.; Besserer-Offroy É.; Murza A.; Tétreault P.; Belleville K.; Ché C.; Larocque A.; Thiot C. Conjugation of a Brain-Penetrant Peptide with Neurotensin Provides Antinociceptive Properties. J. Clin. Invest. 2014, 124 (3), 1199 10.1172/JCI70647. 24531547 PMC3934173 · DOI
  41. Molino Y.; David M.; Varini K.; Jabès F.; Gaudin N.; Fortoul A.; Bakloul K.; Masse M.; Bernard A.; Drobecq L. Use of LDL Receptor–Targeting Peptide Vectors for in Vitro and in Vivo Cargo Transport Across the Blood-Brain Barrier. FASEB J. 2017, 31 (5), 1807– 1827. 10.1096/fj.201600827R. 28108572 · DOI
  42. Morales-Zavala F.; Arriagada H.; Hassan N.; Velasco C.; Riveros A.; Álvarez A. R.; Minniti A. N.; Rojas-Silva X.; Muñoz L. L.; Vasquez R. Peptide Multifunctionalized Gold Nanorods Decrease Toxicity of β-Amyloid Peptide in a Caenorhabditis Elegans Model of Alzheimer’s Disease. Nanomedicine: Nanotechnology, Biology and Medicine 2017, 13 (7), 2341– 2350. 10.1016/j.nano.2017.06.013. 28673851 · DOI
  43. Eggert S.; Thomas C.; Kins S.; Hermey G. Trafficking in Alzheimer’s Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin. Molecular neurobiology 2018, 55 (7), 5809– 5829. 10.1007/s12035-017-0806-x. 29079999 · DOI
  44. Wang R.; Wang C.; Dai Z.; Chen Y.; Shen Z.; Xiao G.; Chen Y.; Zhou J.-N.; Zhuang Z.; Wu R. An Amyloid-β Targeting Chemical Exchange Saturation Transfer Probe for In Vivo Detection of Alzheimer’s Disease. ACS Chem. Neurosci. 2019, 10 (8), 3859– 3867. 10.1021/acschemneuro.9b00334. 31343167 · DOI
  45. Van Groen T.; Kadish I.; Wiesehan K.; Funke S. A.; Willbold D. In Vitro and in Vivo Staining Characteristics of Small, Fluorescent, Abeta-42-Binding D-Enantiomeric Peptides in Transgenic AD Mouse Models. ChemMedChem. 2009, 4 (2), 276– 82. 10.1002/cmdc.200800289. 19072935 · DOI
  46. Funke S. A.; van Groen T.; Kadish I.; Bartnik D.; Nagel-Steger L.; Brener O.; Sehl T.; Batra-Safferling R.; Moriscot C.; Schoehn G. Oral Treatment with the D-Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer’s Disease Transgenic Mice. ACS chemical neuroscience 2010, 1 (9), 639– 648. 10.1021/cn100057j. 22778851 PMC3368690 · DOI
  47. Wiesehan K.; Buder K.; Linke R. P.; Patt S.; Stoldt M.; Unger E.; Schmitt B.; Bucci E.; Willbold D. Selection of D-amino-Acid Peptides that Bind to Alzheimer’s Disease Amyloid Peptide abeta1–42 by Mirror Image Phage Display. Chembiochem: a European journal of chemical biology 2003, 4 (8), 748– 53. 10.1002/cbic.200300631. 12898626 · DOI
  48. Van Groen T.; Wiesehan K.; Funke S. A.; Kadish I.; Nagel-Steger L.; Willbold D. Reduction of Alzheimer’s Disease Amyloid Plaque Load in Transgenic Mice by D3, ad-Enantiomeric Peptide Identified by Mirror Image Phage Display. ChemMedChem: Chemistry Enabling Drug Discovery 2008, 3 (12), 1848– 1852. 10.1002/cmdc.200800273. 19016284 · DOI
  49. Funke S. A.; Bartnik D.; Glück J. M.; Piorkowska K.; Wiesehan K.; Weber U.; Gulyas B.; Halldin C.; Pfeifer A.; Spenger C. Development of a Small D-Enantiomeric Alzheimer’s Amyloid-β Binding Peptide Ligand for Future in Vivo Imaging Applications. PloS one 2012, 7 (7), e41457 10.1371/journal.pone.0041457. 22848501 PMC3404088 · DOI
  50. Xia H.; Anderson B.; Mao Q.; Davidson B. L. Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium. Journal of virology 2000, 74 (23), 11359– 11366. 10.1128/JVI.74.23.11359-11366.2000. 11070036 PMC113241 · DOI
  51. Yin T.; Yang L.; Liu Y.; Zhou X.; Sun J.; Liu J. Sialic Acid (SA)-Modified Selenium Nanoparticles Coated with a High Blood–Brain Barrier Permeability Peptide-B6 Peptide for Potential Use in Alzheimer’s Disease. Acta biomaterialia 2015, 25, 172– 183. 10.1016/j.actbio.2015.06.035. 26143603 · DOI
  52. Georgieva J. V.; Hoekstra D.; Zuhorn I. S. Smuggling Drugs into the Brain: an Overview of Ligands Targeting Transcytosis for Drug Delivery Across the Blood–Brain Barrier. Pharmaceutics 2014, 6 (4), 557– 583. 10.3390/pharmaceutics6040557. 25407801 PMC4279133 · DOI · Paper page
  53. Oller-Salvia B.; Sánchez-Navarro M.; Ciudad S.; Guiu M.; Arranz-Gibert P.; Garcia C.; Gomis R. R.; Cecchelli R.; García J.; Giralt E. MiniAp-4: a Venom-Inspired Peptidomimetic for Brain Delivery. Angew. Chem., Int. Ed. 2016, 55 (2), 572– 575. 10.1002/anie.201508445. PMC4736446 26492861 · DOI
  54. Oller-Salvia B.; Teixidó M.; Giralt E. From Venoms to BBB Shuttles: Synthesis and Blood–Brain Barrier Transport Assessment of Apamin and a Nontoxic Analog. Peptide Science 2013, 100 (6), 675– 686. 10.1002/bip.22257. 24281722 · DOI
  55. Wehbe R.; Frangieh J.; Rima M.; El Obeid D.; Sabatier J.-M.; Fajloun Z. Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules 2019, 24 (16), 2997 10.3390/molecules24162997. PMC6720840 31430861 · DOI
  56. Moreno M.; Giralt E. Three Valuable Peptides from Bee and Wasp Venoms for Therapeutic and Biotechnological Use: Melittin, Apamin and Mastoparan. Toxins 2015, 7 (4), 1126– 1150. 10.3390/toxins7041126. 25835385 PMC4417959 · DOI
  57. Fuster C.; Varese M.; García J.; Giralt E.; Sánchez-Navarro M.; Teixidó M. Expanding the MiniAp-4 BBB-Shuttle Family: Evaluation of Proline cis-trans Ratio as Tool to Fine-Tune Transport. Journal of Peptide Science 2019, 25 (5), e3172 10.1002/psc.3172. 31006945 · DOI
  58. Dal Magro R.; Simonelli S.; Cox A.; Formicola B.; Corti R.; Cassina V.; Nardo L.; Mantegazza F.; Salerno D.; Grasso G.; Deriu M. A.; Danani A.; Calabresi L.; Re F. The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier in Vitro. Frontiers in Neuroscience 2019, 13 (419), 1 10.3389/fnins.2019.00419. 31156358 PMC6532439 · DOI
  59. Liu H.; Funke S. A.; Willbold D. Transport of Alzheimer Disease Amyloid-β-Binding d-Amino Acid Peptides Across an in Vitro Blood–Brain Barrier Model. Rejuvenation research 2010, 13 (2–3), 210– 213. 10.1089/rej.2009.0926. 19954305 · DOI
  60. Sakamoto K.; Shinohara T.; Adachi Y.; Asami T.; Ohtaki T. A Novel LRP1-Binding Peptide L57 that Crosses the Blood Brain Barrier. Biochemistry and biophysics reports 2017, 12, 135– 139. 10.1016/j.bbrep.2017.07.003. 29090274 PMC5645116 · DOI
  61. Fernandes J.; Ghate M. V.; Basu Mallik S.; Lewis S. A. Amino Acid Conjugated Chitosan Nanoparticles for the Brain Targeting of a Model Dipeptidyl Peptidase-4 Inhibitor. Int. J. Pharm. 2018, 547 (1), 563– 571. 10.1016/j.ijpharm.2018.06.031. 29906562 · DOI
  62. Gonzalez-Carter D. A.; Ong Z. Y.; McGilvery C. M.; Dunlop I. E.; Dexter D. T.; Porter A. E. L-DOPA Functionalized, Multi-branched Gold Nanoparticles as Brain-Targeted Nano-Vehicles. Nanomedicine: Nanotechnology, Biology and Medicine 2019, 15 (1), 1– 11. 10.1016/j.nano.2018.08.011. 30189294 · DOI
  63. Li L.; Di X.; Wu M.; Sun Z.; Zhong L.; Wang Y.; Fu Q.; Kan Q.; Sun J.; He Z. Targeting Tumor Highly-Expressed LAT1 Transporter with Amino Acid-Modified Nanoparticles: Toward a Novel Active Targeting Strategy in Breast Cancer Therapy. Nanomedicine: Nanotechnology, Biology and Medicine 2017, 13 (3), 987– 998. 10.1016/j.nano.2016.11.012. 27890657 · DOI
  64. Li L.; Di X.; Zhang S.; Kan Q.; Liu H.; Lu T.; Wang Y.; Fu Q.; Sun J.; He Z. Large Amino Acid Transporter 1 Mediated Glutamate Modified Docetaxel-Loaded Liposomes for Glioma Targeting. Colloids Surf., B 2016, 141, 260– 267. 10.1016/j.colsurfb.2016.01.041. 26859117 · DOI
  65. Takahashi Y.; Nishimura T.; Higuchi K.; Noguchi S.; Tega Y.; Kurosawa T.; Deguchi Y.; Tomi M. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm. Res. 2018, 35 (12), 246 10.1007/s11095-018-2532-0. 30374619 PMC6208607 · DOI
  66. Kenett R. S. Z.; Amberti D. Modern Industrial Statistics: with Applications in R, MINITAB and JMP, 2nd ed.; John Wiley and Sons: Chichester, 2014.
  67. Kenett R.; Zacks S. Modern Industrial Statistics: Design and Control of Quality and Reliability; Duxbury press: San Francisco, 1998.
  68. Israel L. L.; Lellouche E.; Kenett R.; Green O.; Michaeli S.; Lellouche J. P. Ce3/4+ Cation-Functionalized Maghemite Nanoparticles Towards siRNA-Mediated Gene Silencing. J. Mater. Chem. B 2014, 2 (37), 6215– 6225. 10.1039/C4TB00634H. 32262139 · DOI
  69. Eikelenboom P.; Van Exel E.; Hoozemans J. J.; Veerhuis R.; Rozemuller A. J.; Van Gool W. A. Neuroinflammation–an Early Event in Both the History and Pathogenesis of Alzheimer’s Disease. Neurodegenerative Diseases 2010, 7 (1–3), 38– 41. 10.1159/000283480. 20160456 · DOI
  70. Dickson T.; Vickers J. The Morphological Phenotype of β-Amyloid Plaques and Associated Neuritic Changes in Alzheimer’s Disease. Neuroscience 2001, 105 (1), 99– 107. 10.1016/S0306-4522(01)00169-5. 11483304 · DOI · Paper page
  71. Smith A. D. Imaging the Progression of Alzheimer Pathology Through the Brain. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (7), 4135– 4137. 10.1073/pnas.082107399. 11929987 PMC123611 · DOI
  72. Masliah E.; Mallory M.; Alford M.; DeTeresa R.; Hansen L.; McKeel D.; Morris J. Altered Expression of Synaptic Proteins Occurs Early During Progression of Alzheimer’s Disease. Neurology 2001, 56 (1), 127– 129. 10.1212/WNL.56.1.127. 11148253 · DOI · Paper page
  73. Bagyinszky E.; Giau V. V.; Shim K.; Suk K.; An S. S. A.; Kim S. Role of Inflammatory Molecules in the Alzheimer’s Disease Progression and Diagnosis. Journal of the neurological sciences 2017, 376, 242– 254. 10.1016/j.jns.2017.03.031. 28431620 · DOI
  74. Veitch D. P.; Weiner M. W.; Aisen P. S.; Beckett L. A.; Cairns N. J.; Green R. C.; Harvey D.; Jack C. R. Jr; Jagust W.; Morris J. C. Understanding Disease Progression and Improving Alzheimer’s Disease Clinical Trials: Recent Highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s & Dementia 2019, 15 (1), 106– 152. 10.1016/j.jalz.2018.08.005. 30321505 · DOI · Paper page
  75. Bourassa P.; Alata W.; Tremblay C.; Paris-Robidas S.; Calon F. Transferrin Receptor-Mediated Uptake at the Blood–Brain Barrier Is Not Impaired by Alzheimer’s Disease Neuropathology. Mol. Pharmaceutics 2019, 16 (2), 583– 594. 10.1021/acs.molpharmaceut.8b00870. 30609376 · DOI
  76. Baloyannis S. Brain Capillaries in Alzheimer’s Disease. Hellenic journal of nuclear medicine 2015, 18, 152. 26665235
  77. Kitaguchi H.; Ihara M.; Saiki H.; Takahashi R.; Tomimoto H. Capillary Beds are Decreased in Alzheimer’s Disease, But Not in Binswanger’s Disease. Neurosci. Lett. 2007, 417 (2), 128– 131. 10.1016/j.neulet.2007.02.021. 17403574 · DOI
  78. Krause G.; Winkler L.; Mueller S. L.; Haseloff R. F.; Piontek J.; Blasig I. E. Structure and Function of Claudins. Biochimica et Biophysica Acta (BBA)-Biomembranes 2008, 1778 (3), 631– 645. 10.1016/j.bbamem.2007.10.018. 18036336 · DOI
  79. Krug S. M.; Günzel D.; Conrad M. P.; Lee I. F. M.; Amasheh S.; Fromm M.; Yu A. S. Charge-Selective Claudin Channels. Ann. N.Y. Acad. Sci. 2012, 1257 (1), 20– 28. 10.1111/j.1749-6632.2012.06555.x. 22671585 · DOI
  80. Tamura A.; Hayashi H.; Imasato M.; Yamazaki Y.; Hagiwara A.; Wada M.; Noda T.; Watanabe M.; Suzuki Y.; Tsukita S. Loss of Claudin-15, But Not Claudin-2, Causes Na+ Deficiency and Glucose Malabsorption in Mouse Small Intestine. Gastroenterology 2011, 140 (3), 913– 923. 10.1053/j.gastro.2010.08.006. 20727355 · DOI
  81. Abadier M.; Lyck R., Pathways Across the Blood-Brain Barrier. In The Blood Brain Barrier and Inflammation, Lyck R.; Enzmann G., Eds.; Springer International Publishing: Cham, 2017; pp 187– 211.
  82. Merico D.; Gfeller D.; Bader G. D. How to Visually Interpret Biological Data Using Networks. Nature biotechnology 2009, 27 (10), 921– 924. 10.1038/nbt.1567. PMC4154490 19816451 · DOI
  83. Lue L.-F.; Pai M.-C.; Chen T.-F.; Hu C.-J.; Huang L.-K.; Lin W.-C.; Wu C.-C.; Jeng J.-S.; Blennow K.; Sabbagh M. N.; Yan S.-H.; Wang P.-N.; Yang S.-Y.; Hatsuta H.; Morimoto S.; Takeda A.; Itoh Y.; Liu J.; Xie H.; Chiu M.-J. Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects. Frontiers in Aging Neuroscience 2019, 11 (222), 1 10.3389/fnagi.2019.00222. 31551751 PMC6734161 · DOI
  84. Mehta P. D.; Pirttila T.; Mehta S. P.; Sersen E. A.; Aisen P. S.; Wisniewski H. M. Plasma and Cerebrospinal Fluid Levels of Amyloid Beta Proteins 1–40 and 1–42 in Alzheimer Disease. Archives of neurology 2000, 57 (1), 100– 5. 10.1001/archneur.57.1.100. 10634455 · DOI · Paper page
  85. Hladky S. B.; Barrand M. A. Elimination of Substances from the Brain Parenchyma: Efflux via Perivascular Pathways and via the Blood–Brain Barrier. Fluids and Barriers of the CNS 2018, 15 (1), 30 10.1186/s12987-018-0113-6. 30340614 PMC6194691 · DOI · Paper page
  86. Dehouck B.; Dehouck M. P.; Fruchart J. C.; Cecchelli R. Upregulation of the Low Density Lipoprotein Receptor at the Blood-Brain Barrier: Intercommunications Between Brain Capillary Endothelial Cells and Astrocytes. J. Cell Biol. 1994, 126 (2), 465– 473. 10.1083/jcb.126.2.465. 8034745 PMC2200038 · DOI
  87. Gosselet F.; Candela P.; Sevin E.; Berezowski V.; Cecchelli R.; Fenart L. Transcriptional Profiles of Receptors and Transporters Involved in Brain Cholesterol Homeostasis at the Blood–Brain Barrier: Use of an in Vitro Model. Brain Res. 2009, 1249, 34– 42. 10.1016/j.brainres.2008.10.036. 18996096 · DOI
  88. Candela P.; Saint-Pol J.; Kuntz M.; Boucau M.-C.; Lamartiniere Y.; Gosselet F.; Fenart L. In Vitro Discrimination of the Role of LRP1 at the BBB Cellular Level: Focus on Brain Capillary Endothelial Cells and Brain Pericytes. Brain Res. 2015, 1594, 15– 26. 10.1016/j.brainres.2014.10.047. 25451130 · DOI
  89. Tian X.; Leite D. M.; Scarpa E.; Nyberg S.; Fullstone G.; Forth J.; Matias D. L.; Apriceno A.; Poma A.; Duro-Castano A.; Vuyyuru M.; Harker-Kirschneck L.; Šarić A.; Zhang Z.; Xiang P.; Fang B.; Tian Y.; Luo L.; Rizzello L.; Battaglia G. On the shuttling across the blood-brain barrier via tubule formation: Mechanism and cargo avidity bias. Sci. Adv. 2020, 6 (48), abc4397 10.1126/sciadv.abc4397. PMC7695481 33246953 · DOI
  90. Cho C. F.; Wolfe J. M.; Fadzen C. M.; Calligaris D.; Hornburg K.; Chiocca E. A.; Agar N. Y. R.; Pentelute B. L.; Lawler S. E. Blood-Brain-Barrier Spheroids as an in Vitro Screening Platform for Brain-Penetrating Agents. Nat. Commun. 2017, 8, 15623 10.1038/ncomms15623. 28585535 PMC5467173 · DOI
  91. Di Guardo G. Lipofuscin, Lipofuscin-Like Pigments and Autofluorescence. European Journal of Histochemistry: EJH 2015, 59 (1), 2485 10.4081/ejh.2015.2485. 25820564 PMC4378218 · DOI
  92. Feldman T. B.; Yakovleva M. A.; Dontsov A. E.; Ostrovsky M. A. Fluorescence Emission and Excitation Spectra of Fluorophores of Lipofuscin Granules Isolated from Retinal Pigment Epithelium of Human Cadaver Eyes. Russian Chemical Bulletin 2010, 59 (1), 276– 283. 10.1007/s11172-010-0073-8. · DOI
  93. Marmorstein A. D.; Marmorstein L. Y.; Sakaguchi H.; Hollyfield J. G. Spectral Profiling of Autofluorescence Associated with Lipofuscin, Bruch’s Membrane, and Sub-RPE Deposits in Normal and AMD Eyes. Investigative Ophthalmology & Visual Science 2002, 43 (7), 2435– 2441. 12091448

Cited by

Sorted by citations

Authors
Israel, L. L., Galstyan, A., Cox, A., Shatalova, E. S., Sun, T., Rashid, M.-H., Grodzinski, Z., Chiechi, A., Fuchs, D.-T., Patil, R., Koronyo-Hamaoui, M., Black, K. L., Ljubimova, J. Y., & Holler, E.
Affiliations
  • Cedars-Sinai Medical Center (US)
  • Department of Neurosurgery and Department of Biomedical Sciences, Division of Applied Cell Biology and Physiology, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
  • Terasaki Foundation (US)
Corresponding author
  • Ljubimova, Julia Y.
  • Holler, Eggehard
ORCID
Venue
ACS Nano
Publisher
American Chemical Society (ACS)
Published
2022-08-12
Volume
16
Issue
8
Pages
11815-11832
ISSN
  • 1936-0851 (ISSN-L)
  • 1936-086X
DOI
10.1021/acsnano.1c10034
PMC
PMC9413444
OpenAlex
W4290960196
Cited by
41
References
10
Citations by year
2026: 10 · 2025: 18 · 2024: 5 · 2023: 8
FWCI
2.72
Type
journal article
Language
en
Open access
Licence
Locations
  • ACS Nano (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Funders
  • National Cancer Institute (CA 206220, CA 209921, CA188743)
  • Health Effects of Air Pollution Foundation Agreement (BTAP011, BTAP013, HEAPF015)
  • Department of Neurosurgery, Cedars-Sinai Medical Center
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
blood-brain barrier permeability, Alzheimer's disease, glioblastoma, transcytosis, peptide vectors, transferrin receptor, dose dependence
MeSH terms
Alzheimer Disease, Animals, Blood-Brain Barrier, Peptides, Polymers, Amyloid beta-Peptides, Mice, Transcytosis, Nanoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review